M.J. Biopharm

M.J. Biopharm is a specialized biopharmaceutical company based in India, primarily focused on the production of insulin and its analogs for the treatment of diabetes. Established in 1997, the company has developed robust capabilities in recombinant DNA technology, allowing it to manufacture high-quality biosimilar insulin products. Their portfolio includes human insulin, insulin glargine, and insulin lispro, alongside oral anti-diabetic medications like metformin. M.J. Biopharm operates advanced manufacturing facilities in Navi Mumbai that adhere to international regulatory standards, including WHO-GMP. The company serves a diverse global clientele, exporting life-saving medications to over 40 countries across emerging markets.